Safety and Pharmacology of SNX-5422 Mesylate in Subjects With Refractory Solid Tumor Malignancies

Safety and Pharmacology of SNX-5422 Mesylate in Subjects With Refractory Solid Tumor Malignancies

Solid Tumors

Completed

1

Start Date 06/15/2007

Age of Trial (yrs) 18.4

Gleevec-resistant

HSP90 inhibitor

Destroy KIT

GIST not specified. GIST patient enrollment unknown.

SNX-5422-CLN1-001

Pfizer Serenex, Inc.

Pfizer Oncology Clinical Trial Information 1-877-369-9753 PfizerCancerTrials@emergingmed.com Pfizer CT.gov Call Center 1-800-718-1021

Oral

Note: The development of SNX-5422 has been discontinued because of ocular toxicity seen in animal models and in a phase I study. Clin Cancer Res; 17(21); 1–9. ©2011 AACR.
Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.
Study Type: Interventional
Study Design: Treatment, Open Label, Uncontrolled, Single Group Assignment, Safety Study
Number of arms in study: 1
Primary Outcome Measures:

* adverse events and other safety assessments [Time Frame: continuous]


Secondary Outcome Measures:

* tumor response measured by X-rays or scans [Time Frame: after every 2 cycles]